Growth factors

BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies

Retrieved on: 
Thursday, December 19, 2019
Medicine, Chemistry, Clinical medicine, RTT, Blood disorders, Oncology, Amgen, Growth factors, Granulocyte colony-stimulating factor, Plinabulin, Cytopenia, Docetaxel

The report demonstrates that Plinabulin can successfully treat chemotherapy-induced neutropenia (CIN) caused by multiple chemotherapies.

Key Points: 
  • The report demonstrates that Plinabulin can successfully treat chemotherapy-induced neutropenia (CIN) caused by multiple chemotherapies.
  • In addition, Plinabulin has positive effects on bone marrow cells, with a mechanism distinct from G-CSF-based therapies, the current standard of care for CIN.
  • The paper, titled, Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from GCSF therapies, reports on Plinabulins ability to reduce neutropenia induced by docetaxel, cyclophosphamide or doxorubicin chemotherapy, without affecting bone marrow or blood G-CSF levels.
  • In line with this potential, Plinabulin alleviates docetaxel-induced thrombocytopenia, as well as neutropenia, in NSCLC patients.

Global Chemotherapy-Induced Anemia Market Spotlight Report 2019: Pfizer's Epogen Biosimilar Retacrit Launches at 33% Off in a US Market where Amgen's Already Competitive - ResearchAndMarkets.com

Retrieved on: 
Monday, December 2, 2019
Health, Clinical trials, Medicine, Health, Clinical medicine, RTT, Growth factors, Antineoplastic drugs, Oncology, Amgen, Chemotherapy, Anemia, Erythropoietin, Clinical trial

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy.
  • The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
  • Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.

The Erythropoietin Stimulating Agents Market in Latin America (2019-2027): Data on Epoetin-Alfa, Epoetin-Beta, Epoetin-Theta, Darbepoetin-Alfa, and Other ESAs

Retrieved on: 
Wednesday, November 27, 2019
Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Cytokines, Erythropoietin, Hematopoiesis, Erythropoiesis-stimulating agent, Erythropoiesis

DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

Latin America's $534M Erythropoietin Stimulating Agents Market, 2019-2027: Demand Analysis & Opportunity Evaluation - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 26, 2019
Health, Pharmaceutical, Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Erythropoiesis-stimulating agents, Cytokines, Erythropoietin, Erythropoiesis

The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

Retrieved on: 
Saturday, November 23, 2019
Branches of biology, Cell signaling, Tyrosine kinase receptors, Cell biology, Growth factors, Proteins, VEGF receptor, Vascular endothelial growth factor, Eli Lilly and Company, Tyrosine kinase inhibitors

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3.

Key Points: 
  • Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3.
  • Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.
  • Chi-Med retains all rights to fruquintinib outside of China and is partnered with Eli Lilly and Company in China.
  • Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products.

Forbius to Present at Jefferies 2019 London Healthcare Conference

Retrieved on: 
Monday, November 18, 2019
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Growth factors, Signal transduction, Transforming growth factor beta, Endoglin, Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer, TGF-beta 1 & 3

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that Forbius management will present a company overview at the Jefferies 2019 Healthcare Conference on Thursday, November 21, 2019 at 07:20 a.m. GMT in London.

Key Points: 
  • Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that Forbius management will present a company overview at the Jefferies 2019 Healthcare Conference on Thursday, November 21, 2019 at 07:20 a.m. GMT in London.
  • Forbius is a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer.
  • Forbius team of TGF-beta biology experts designed a proprietary platform of TGF-beta inhibitors with best-in-class potency and selectivity against the principal disease-driving isoforms 1 & 3.
  • Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Press release - Parliament backs €1.6 million to help former workers of Carrefour Belgium

Retrieved on: 
Thursday, November 14, 2019
Economy of the European Union, European Globalisation Adjustment Fund, Growth factors, EGF, Morphogens, Jos, Epidermal growth factor

The total estimated funding amounts to 2.7 million, of which the EGF would provide 60% (1.6 million).

Key Points: 
  • The total estimated funding amounts to 2.7 million, of which the EGF would provide 60% (1.6 million).
  • The draft report by Jos Manuel Fernandes (EPP, PT), recommending that Parliament approve the aid, was passed by 558 votes to 63, and 43 abstentions.
  • Background

    The European Globalisation Adjustment Fund (EGF) contributes to packages of tailor-made services to help redundant workers find new jobs.

  • According to the Belgian Federation for Commerce and Services, 67% of Belgian consumers shopped online in 2018 - up from 46% in 2012.

Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease

Retrieved on: 
Saturday, November 9, 2019
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Branches of biology, Medical specialties, Medicine, Growth factors, RTT, Erythropoiesis-stimulating agents, Acetic acids, Organ failure, Vadadustat, Epoetin alfa, Chronic kidney disease, Anemia, Akebia Therapeutics, Vadadustat

Correcting and maintaining hemoglobin levels within a target range is paramount in the treatment of anemia due to chronic kidney disease, said John P. Butler, President and Chief Executive Officer of Akebia.

Key Points: 
  • Correcting and maintaining hemoglobin levels within a target range is paramount in the treatment of anemia due to chronic kidney disease, said John P. Butler, President and Chief Executive Officer of Akebia.
  • The 52-week data from MTPCs studies reinforce our belief in vadadustats potential to make a difference in the lives of people impacted by anemia due to CKD.
  • The incidence of adverse events (AEs) was 90.1% in the vadadustat-treated group compared to 92.2% in the darbepoetin alfa-treated group.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease.

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

Retrieved on: 
Friday, November 8, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Proteins, Transforming growth factor beta, Cell biology, TGF beta 1, Transcription factors, Growth factors, Signal transduction, TGF beta Activation, SMAD, TGF-beta 1 & 3, Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer

AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms.

Key Points: 
  • AVID200 is a first-in-class, selective inhibitor of TGF-beta 1 & 3, the main pathogenic TGF-beta isoforms.
  • AVID200 achieved dose-proportional exposure and exhibited peripheral target inhibition of TGF-beta 1 & 3 over the entire dosing period at all dose levels tested.
  • Several patients experienced stable disease including one patient with prolonged stable disease of more than 8 months who continues on treatment.
  • Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

Retrieved on: 
Wednesday, November 6, 2019
Branches of biology, Growth factors, TLR7, Tyrosine kinase inhibitor, Vascular endothelial growth factor, Resiquimod

TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod that is transiently conjugated to a hydrogel carrier via a TransCon linker.

Key Points: 
  • TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod that is transiently conjugated to a hydrogel carrier via a TransCon linker.
  • Administered as an intratumoral injection, TransCon TLR7/8 Agonist is designed to provide sustained release of unmodified resiquimod directly to the tumor.
  • Three oncology programs are currently in preclinical studies: TransCon TLR7/8 Agonist, TransCon IL-2 b/g and TransCon Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI).
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.